↓ Skip to main content

Dove Medical Press

Article Metrics

Rituximab for the treatment of rheumatoid arthritis: an update

Overview of attention for article published in Drug Design, Development and Therapy, December 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

policy
1 policy source
twitter
6 tweeters

Citations

dimensions_citation
92 Dimensions

Readers on

mendeley
193 Mendeley
Title
Rituximab for the treatment of rheumatoid arthritis: an update
Published in
Drug Design, Development and Therapy, December 2013
DOI 10.2147/dddt.s41645
Pubmed ID
Authors

Chi Chiu Mok

Abstract

Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule expressed on the surface of B cells. It was first used in the treatment of non-Hodgkin's lymphoma and later approved for the treatment of rheumatoid arthritis (RA) that does not respond adequately to disease-modifying antirheumatic drugs, including the anti-tumor-necrosis-factor (TNF) biologics. Sustained efficacy in RA can be achieved by repeated courses of rituximab. However, the optimal dose and retreatment schedule of rituximab in RA remains to be established. Seropositivity, complete B cell depletion shortly after treatment, and previous failure to no more than one anti-TNF agent are three factors associated with greater clinical benefits to rituximab. Infusion reaction to the first dose of rituximab occurs in approximately 25% of RA patients, and the incidence reduces with subsequent exposure. Immunogenicity to the chimeric compound occurs in 11% of RA patients, but this does not correlate with its efficacy in B cell depletion. Extended observation of randomized controlled trials in RA does not reveal a significant increase in the incidence of serious infections related to rituximab compared to placebo groups, and the infection rate remains static over time. Repeated treatment with rituximab is associated with hypogammaglobulinemia, which may increase the risk of serious, but rarely opportunistic, infections. Reactivation of occult hepatitis B infection has been reported in RA patients receiving rituximab, but no increase in the incidence of tuberculosis was observed. Screening for baseline serum immunoglobulin G level and hepatitis B status (including occult infection) is important, especially in Asian countries where hepatitis B infection is prevalent. The rare but fatal progressive multifocal leukoencephalopathy linked to the use of rituximab has to be noted. Postmarketing surveillance and registry data, particularly in Asia, are necessary to establish the long-term efficacy and safety of rituximab in the treatment of RA.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Netherlands 1 <1%
Colombia 1 <1%
Unknown 190 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 39 20%
Student > Ph. D. Student 30 16%
Student > Master 29 15%
Researcher 16 8%
Other 15 8%
Other 30 16%
Unknown 34 18%
Readers by discipline Count As %
Medicine and Dentistry 70 36%
Pharmacology, Toxicology and Pharmaceutical Science 20 10%
Agricultural and Biological Sciences 19 10%
Biochemistry, Genetics and Molecular Biology 16 8%
Immunology and Microbiology 12 6%
Other 16 8%
Unknown 40 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2019.
All research outputs
#3,058,540
of 17,353,889 outputs
Outputs from Drug Design, Development and Therapy
#155
of 1,713 outputs
Outputs of similar age
#46,348
of 273,421 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 53 outputs
Altmetric has tracked 17,353,889 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,713 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,421 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.